August 16, 2019 / 2:46 PM / a month ago

BRIEF-Roche Announces Monthly and Yearly Rozlytrek Treatment Costs In U.S.

Aug 16 (Reuters) - Roche Holding AG:

* ROCHE - MONTHLY COST OF ROZLYTREK FOR ADULTS WITH ROS1-POSITIVE METASTATIC NSCLC & FOR ADULTS WITH NTRK FUSION-POSITIVE SOLID TUMOURS IS ABOUT $17,050

* ROCHE - ANNUAL COST OF TREATMENT WITH ROZLYTREK IS ABOUT $204,560 Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below